Evaluation of bone metabolic markers in breast cancer with bone metastasis

被引：50

作者：

Wada N. ^{[1
,3
]}

Fujisaki M. ^{[1
]}

Ishii S. ^{[2
]}

Ikeda T. ^{[3
]}

Kitajima M. ^{[3
]}

机构：

[1] Department of Surgery, Ashikaga Red Cross Hospital, Ashikaga, Tochigi 326-0808

[2] Department of Surgery, Kawasaki City Hospital

[3] Department of Surgery, Keio University, School of Medicine

来源：

Breast Cancer | 2001年 / 8卷 / 2期

关键词：

Bone metabolic marker; Bone metastasis; Breast cancer; Carboxyterminal telopeptide of type I collagen; Tartrate resistant acid phosphatase;

D O I：

10.1007/BF02967492

中图分类号：

学科分类号：

摘要：

Purpose: In the present study, four bone metabolic markers were examined to clarify them meaning and clinical value in the detection of bone metastasis (BM) from breast cancer. Methods: we examined serum carboxyterminal telopeptide of type I collagen (ICTP), tartrate resistant acid phosphatase (TRACP), total alkaline phosphatase (ALP) and urinary type I collagen cross-linked N-telopeptides (NTx) as potential markers. These bone markers were evaluated simultaneously in 156 breast cancer patients; 114 patients without metastasis (group A), 23 patients with BM (group B) and 19 patients with metastasis at sites other than bone (group C). Results: The mean values of ICTP and TRACP in group B were significantly greater than those in group A. Group B consisted of the patients with varying degrees of BM and variation in their treatments. The patients in group B were divided into BM (+) and BM (++) according to hot spots in bone scan. ICTP and TRACP were elevated in BM (++) patients compared to BM (+) patients (p<0.05). The values of ICTP and TRACP of the twelve patients without treatment in group B were significantly higher than those in group A. In the treated patients of group B, the mean values of ICTP and TRACP were lower in responders and cases of stable disease than those with progression. NTx and ALP were inferior to ICTP and TRACP for clinical evaluation of BM. Conclusions: We confirmed that ICTP and TRACP might be useful markers for screening and monitoring BM in breast cancer.

引用

页码：131 / 137

页数：6

共 25 条

[1]

Coleman R.E., Rubens R.D., The clinical course of bone metastases from breast cancer, British Journal of Cancer, 55, 1, pp. 61-66, (1987)

[2]

Osawa S., Iida S., Yonemitsu H., Et al., Prostatic acid phosphatase assay with self-indicating substrate 2,6-dichloro-4-acetylphenyl phosphate, Clin Chem, 41, pp. 200-203, (1995)

[3]

Risteli J., Elomaa I., Niemi S., Novamo A., Risteli L., Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation, Clinical Chemistry, 39, 4, pp. 635-640, (1993)

[4]

Hanson D.A., Weis M.A.E., Bollen A.-M., Maslan S.L., Singer F.R., Eyre D.R., A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine, Journal of Bone and Mineral Research, 7, 11, pp. 1251-1258, (1992)

[5]

Eyre D., New biomarkers of bone resorption, J Clin Endocrinol Metabo, 74, (1992)

[6]

General Rules for Clinical and Pathological Recording of Breast Cancer, (1998)

[7]

Desoize B., Delvincourt C., Comoe L., Comparison of 4 techniques of alkaline phosphatase isoenzyme assay, Clinical Chemistry and Enzymology Communications, 2, 2, pp. 107-114, (1990)

[8]

Minkin C., Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function, Calcified Tissue International, 34, 3, pp. 285-290, (1982)

[9]

Stepan J.J., Zichova M., Lachmanova J., Et al., Plasma tartrate resistant acid phosphatase: A marker for osteoclastic bone resorption, Acta Univ Carol Med Praha, 32, pp. 345-353, (1986)

[10]

Chambers T.J., Fuller K., Darby J.A., Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone, Journal of Cellular Physiology, 132, 1, pp. 90-96, (1987)

← 1 2 3 →